INMUNE BIO INC. (INMB) Return on equity 2017–2025
INMUNE BIO INC. (INMB) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-195.3%FY2025 · since FY2017: -4.6% → -195.3%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -195.3% | -64.2 pp |
| FY2024 | -131.1% | -50.7 pp |
| FY2023 | -80.4% | -34.9 pp |
| FY2022 | -45.4% | -7.6 pp |
| FY2021 | -37.8% | -6.6 pp |
| FY2020 | -31.2% | — |
| FY2018 | -75.2% | -70.6 pp |
| FY2017 | -4.6% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More INMB financial trends
INMB RevenueINMB Net incomeINMB Net marginINMB Gross profitINMB Gross marginINMB Operating incomeINMB Operating marginINMB Operating cash flowINMB Free cash flowINMB Capital expendituresINMB Stock buybacksINMB Dividends paidINMB Total assetsINMB Total liabilitiesINMB Shareholders’ equityINMB overview →